ClinicalTrials.gg
RecruitingNCT06696079RELACSUpdated Aug 22, 2025

Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation

An interventional study of Early Resumption of Oral Anticoagulation Therapy and Late Resumption of Oral Anticoagulation Therapy in Chronic Subdural Hematoma and Atrial Fibrillation (AF), sponsored by Rahul Raj. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Rahul Raj · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this randomized clinical trial is to assess the benefit of early resumption versus late resumption of oral anticoagulation medication in adults with atrial fibrillation undergoing surgery for chronic subdural hematoma. The main questions it aims to answer are:

  • Does anticoagulation resumption 5 days after surgery as compared to 30 days after surgery result in fewer thromboembolic complications, without increasing the risk for bleeding?
  • Does anticoagulation resumption 5 days after surgery as compared to 30 days after surgery affect the risk of reoperation, functional outcome, mortality, and healthcare use?

Researchers will compare early anticoagulation resumption (5 days) and late anticoagulation resumption (30 days) after chronic subdural hematoma surgery.

Participants will either resume the medication 5 days or 30 days after the surgery. The participants will be followed up for 3 months after the surgery.

02

Conditions studied

  • Chronic Subdural Hematoma
  • Atrial Fibrillation (AF)

Keywords

  • chronic subdural hematoma
  • atrial fibrillation
  • oral anticoagulation
  • warfarin
  • direct oral anticoagulants
  • surgery
  • stroke
  • hemorrhage
  • prognosis
03

In context

Hematoma, Subdural, Chronic

113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.

This study's planned enrollment of 332 is above the median of 180 across 87 interventional studies indexed under Hematoma, Subdural, Chronic.

Browse Hematoma, Subdural, Chronic studies →

Lead sponsor

This is the only study on the registry with Rahul Raj as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Patients with a symptomatic unilateral or bilateral CSDH requiring burr-hole evacuation with drainage (CSDH is predominantly hypodense or isodense on imaging [CT/MRI]; clinical symptoms attributable to the CSDH; patients with bilaterally operated CSDHs will be treated with the same protocol on both sides and analyzed as a single study participant).
  • Patients that are on an oral anticoagulation medication due to permanent, persistent or paroxysmal spontaneous atrial fibrillation previously known
  • Randomization done within 4 days of the surgery

Exclusion criteria

Exclusion Criteria:

  • Intraoperative or immediate postoperative hemorrhagic complication
  • CSDH requiring surgical treatment other than burr-hole evacuation (e.g. craniotomy)
  • Prior CSDH surgery within 12 months
  • Cerebrospinal fluid shunt
  • CSDH is in an arachnoid cyst
  • If the operated hematoma is revealed to be a cerebrospinal fluid collection (hygroma)
  • Conditions other than atrial fibrillation that require anticoagulation, including therapeutical dose of low molecular-weight heparin or heparin (for example, pulmonary embolism, deep vein thrombosis, hypercoagulability syndromes)
  • Mechanical heart valve(s)
  • Moderate or severe mitral stenosis (other valvular diseases and biological valves are eligible)
  • to anticoagulation medication (for example bleeding disorder, documented high risk of fall [e.g. due to severe alcoholism], severe thrombocytopenia, severe anemia)
  • Concomitant use of antiplatelet medication
  • Moderate to severe renal insufficiency ( \<30 ml/min or on dialysis)
  • Not a permanent resident in Finland (for Finnish patients) or not a permanent resident in Region Stockholm (for Swedish patients)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
332 participants (estimated)

Study arms

  • Experimental
    Early resumption

    Oral anticoagulation therapy is resumed on the 5th postoperative day following burr-hole surgery for chronic subdural hematoma.

    Drug: Early Resumption of Oral Anticoagulation Therapy

  • Active comparator
    Late resumption

    Oral anticoagulation therapy is resumed on the 30th postoperative day following burr-hole surgery for chronic subdural hematoma.

    Drug: Late Resumption of Oral Anticoagulation Therapy

Interventions

  • DrugEarly Resumption of Oral Anticoagulation Therapy

    The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 5th postoperative day following burr-hole surgery for chronic subdural hematoma. This early resumption strategy is compared to the standard practice of resuming anticoagulation therapy on the 30th postoperative day.

  • DrugLate Resumption of Oral Anticoagulation Therapy

    The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 30th postoperative day following burr-hole surgery for chronic subdural hematoma. This standard resumption strategy is compared to the early approach of resuming anticoagulation therapy on the 5th postoperative day.

06

What researchers measure

Primary outcomes

  1. Rate of composite outcome of vascular events

    Rate of the composite outcome that combines thromboembolic events (ischemic stroke, systemic embolism), hemorrhagic events (intracranial hemorrhage, major extracranial bleeding), and vascular death.

    Time frame: 90 days

Secondary outcomes

  1. Rate of different components of the primary composite outcome

    Separation of the components of the primary composite outcome (thromboembolic, hemorrhagic, vascular death).

    Time frame: 90 days

  2. Rate of patients with favorable functional outcome

    Assessed using the modified Rankin Scale (mRS), which ranges from 0 (no symptoms) to 6 (death).

    Time frame: 90 days

  3. Rate of reoperation

    Reoperation for the initially treated chronic subdural hematoma.

    Time frame: 90 days

  4. Rate of all-cause mortality

    Time frame: 90 days and 12 months

  5. Participants' healthcare use

    Number and type of unscheduled emergency radiological examinations, - number of emergency department visits, postoperative total hospitalization days

    Time frame: 90 days

07

Study locations

1 of 6 sites recruiting
  • Oulu University Hospital
    Oulu, North Ostrobothnia 90220, Finland
    Not yet recruiting
    • Oula Knuutinen, MD, PhD · Contactoula.knuutinen@oulu.fi · ‭+358405842879‬
    • Oula Knuutinen, MD, PhD · Principal investigator
    • Tommi Korhonen, MD, PhD · Sub investigator
    • Sami Tetri, MD, PhD · Sub investigator
  • Kuopio University Hospital
    Kuopio, Northern Savonia 70200, Finland
    Not yet recruiting
    • Nils Danner, MD, PhD · Contactnils.danner@pshyvinvointialue.fi · ‭+358400911568‬
    • Nils Danner, MD, PhD · Principal investigator
    • Ville Leinonen, MD, PhD · Sub investigator
    • Timo Koivisto, MD, PhD · Sub investigator
  • Tampere University Hospital
    Tampere, Pirkanmaa 33520, Finland
    Not yet recruiting
    • Teemu Luoto, MD, PhD · Contactteemu.luoto@pirha.fi · ‭+35840703 9696‬
    • Teemu Luoto, MD, PhD · Principal investigator
    • Minna J Rauhala, MD, PhD · Sub investigator
  • Turku University Hospital
    Turku, Southwest Finland 20520, Finland
    Not yet recruiting
    • Jussi P Posti, MD, PhD · Contactjussi.posti@tyks.fi · ‭+358443804143‬
    • Jussi P Posti, MD, PhD · Principal investigator
    • Dan Laukka, MD, PhD · Sub investigator
  • Helsinki University Hospital
    Helsinki, Uusimaa 00260, Finland
    Recruiting
    • Rahul Raj, MD, PhD · Contactrahul.raj@hus.fi · +358504272516
    • Jarno Satopää, MD, PhD · Contactjarno.satopaa@hus.fi · +358504286743‬
    • Pihla Tommiska, MD, PhD · Sub investigator
    • Miikka Korja, MD, PhD · Sub investigator
    • Riku Kivisaari, MD, PhD · Sub investigator
    • Teemu Luostarinen, MD, PhD · Sub investigator
    • Jyri J Virta, MD, PhD · Sub investigator
    • Simo Taimela, MD, PhD · Sub investigator
    • Teppo LN Järvinen, MD, PhD · Sub investigator
    • Rahul Raj, MD, PhD · Principal investigator
    • Jarno Satopää, MD, PhD · Principal investigator
  • Karolinska University Hospital
    Stockholm, Region Stockholm 17164, Sweden
    Not yet recruiting
    • Jiri Bartek, MD, PhD · Contactjiri.bartek@regionstockholm.se · +46707948670‬
    • Jiri Bartek, MD, PhD · Principal investigator
    • Alexander Fletcher-Sandersjöö, MD, PhD · Sub investigator
    • Bjartur Saemundsson, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Researcher-initiated data sharing is not possible due to the Finnish Secondary Use Act (552/2019). Thus, all requests to process data for purposes permitted by the Secondary Use Act are given based on an official decision made by FINDATA (https://findata.fi/en/).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 44 interventional studies with no phase under Hematoma, Subdural, Chronic, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 19, 2024
StartActual
Jul 7, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06696079
Lead sponsor
Rahul Raj
Responsible party
Rahul Raj (Sponsor Principal Investigator, Helsinki University Central Hospital) — Sponsor-investigator
First posted
Nov 19, 2024
Start date
Jul 7, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 22, 2025

Study contacts

Rahul Raj, MD, PhD
Contact
rahul.raj@hus.fi
+358504272516
Jarno Satopää, MD, PhD
Contact
jarno.satopaa@hus.fi
+358504286743‬
Rahul Raj, MD, PhD
study chair · Helsinki University Hospital & University of Helsinki
Jarno Satopää, MD, PhD
principal investigator · Helsinki University Hospital & University of Helsinki
Jussi P Posti, MD, PhD
principal investigator · Turku University Hospital and University of Turku
Teemu Luoto, MD, PhD
principal investigator · Tampere University Hospital and Tampere University
Nils Danner, MD, PhD
principal investigator · Kuopio University Hospital and University of Eastern Finland
Oula Knuutinen, MD, PhD
principal investigator · Oulu University Hospital and University of Oulu
Jiri Bartek, MD, PhD
principal investigator · Karolinska University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion